Depressing News for Drugmakers

• Report this Comment On November 21, 2008, at 6:40 AM, 4mythreegirls wrote:

  This is flawed study that has limitations. It is another jab at trying to get physicians to utilize more generics. If you look at anti-depressant studies they "work" approximately 48% of the time which means there is plenty of switching and room for all the antidepressants. In addition, they only looked at Response which by definition is a 50% improvement in symptoms - physicians all ready know that all the antidepressants work. The more stringent criteria is Remission (or fully well over a long period of time) and the currently available branded SRI - SNRI have proven over time to achieve remission. Lastly, managed care coverage plays a huge roll in how often these medicines get prescribed. Recently, branded medicines have been put back on formularies that previously removed them. This is because the medical community knows and understands the differences and demanded that the branded medicines become available at a lower co-pay.

• Report this Comment On January 20, 2009, at 8:42 PM, GoNuke wrote:

  This kind of study is tragic. Most people familiar with antidepressants: doctors who prescribe and patients who consume, know that most antidepressants don't work very well for most people. The good news is that there is usually at least one antidepressant that will work well for each individual. It is pretty normal for a depressed patient to try a number of competing antidepressants before finding the one that works for them. Given how long it takes to reach a therapeutic dosage and the 6 weeks you need to spend at a certain dosage before concluding that it does or doesn't work, finding the right med is time consuming.

  The findings of this study suggest that the research team doesn't understand what they were studying.

  Note to investors: ignore these results. They are meaningless.

Add your comment.